In MC or severe exacerbations insufficiently responsive to standard treatment with IVIg and PLEX/IA, add-on C5-I therapy may represent an effective therapeutic approach. Importantly, TAMG, a subtype typically excluded from interventional trials yet often requiring more intensive therapy, also demonstrated clinical improvement. These findings warrant further systematic evaluation of C5-I as adjunctive therapy for AChR-ab+ therapy-refractory MC.
Gerischer et al. (Wed,) studied this question.